The Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional) funding from the National Institutes of Health seeks applications proposing the innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of drug-using behaviors (defined as alcohol, tobacco, prescription and other drugs) and related disorders, prevention of drug use and HIV, and health service utilization. Applications are open to researchers at research institutions in the USA and worldwide. Applications are also open to small businesses. Applicants may apply for up to 275,000 USD direct costs for up to 2 years.
Opportunity number: RFA-DA-24-037.
There are three assessment rounds per year, the next letters of intent are due on July 9, 2023 and full applications are due on August 9, 2023.
